Lysophosphatidic acid induces urokinase secretion by ovarian cancer cells.

Single-Step Method of RNA Isolation by Acid Guanidinium Thiocyanate–Phenol–Chloroform Extraction

1987 • 64,270 citations

Electrophoretic analysis of plasminogen activators in polyacrylamide gels containing sodium dodecyl sulfate and copolymerized substrates

1980 • 1,991 citations

Proteolytic remodeling of extracellular matrix

1995 • 1,086 citations

Lysophosphatidic Acid as a Potential Biomarker for Ovarian and Other Gynecologic Cancers

1998 • 642 citations

Molecular Cloning and Characterization of a Novel Human G-protein-coupled Receptor, EDG7, for Lysophosphatidic Acid

1999 • 517 citations

Diversity of cellular receptors and functions for the lysophospholipid growth factors lysophosphatidic acid and sphingosine 1‐phosphate

1998 • 516 citations

The plasminogen system and cell surfaces: evidence for plasminogen and urokinase receptors on the same cell type.

1986 • 466 citations

Proteases as prognostic markers in cancer.

1996 • 319 citations

Lysophospholipids activate ovarian and breast cancer cells

1995 • 289 citations

Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients.

1992 • 239 citations

Characterization of cultured human ovarian surface epithelial cells: phenotypic plasticity and premalignant changes.

1994 • 188 citations

Induction of in Vitro Tumor Cell Invasion of Cellular Monolayers by Lysophosphatidic Acid or Phospholipase D

1993 • 185 citations

Urokinase‐type plasminogen activator mediates basic fibroblast growth factor‐induced bovine endothelial cell migration independent of its proteolytic activity

1992 • 183 citations

Malignant effusions contain lysophosphatidic acid (LPA)-like activity

1998 • 178 citations

Overexpression of the Protien Tyrosine Phosphatase PTP1B in Human Breast Cancer: Assocation With p185c-erbB-2 Protein Expression

1994 • 170 citations

Growth factor-like effects of lysophosphatidic acid, a novel lipid mediator

1994 • 152 citations

Urokinase (uPA) and PAI-1 Predict Survival in Advanced Ovarian Cancer Patients (FIGO III) after Radical Surgery and Platinum-Based Chemotherapy

1994 • 140 citations

Secretion of extracellular matrix‐degrading proteinases is increased in epithelial ovarian carcinoma

1994 • 120 citations

Primary tumor and metastasis in ovarian cancer differ in their content of urokinase-type plasminogen activator, its receptor, and inhibitors types 1 and 2.

1995 • 96 citations

The significance of urokinase-type plasminogen activator, its inhibitors, and its receptor in ascites of patients with epithelial ovarian cancer

1995 • 79 citations

Plasminogen activators and plasminogen activator inhibitors in blood and tumour fluids of patients with ovarian cancer

1994 • 63 citations

Cell membrane receptors for urokinase plasminogen activator are increased in malignant ovarian tumours

1991 • 59 citations

Urokinase-type plasminogen activator and malignancy

1993 • 56 citations

Effects of urinary trypsin inhibitor on the invasion of reconstituted basement membranes by ovarian cancer cells

1994 • 40 citations

Coordinate expression of urinary-type plasminogen activator and its receptor accompanies malignant transformation of the ovarian surface epithelium

1994 • 37 citations

Examination of urokinase protein/transcript levels and their relationship with laminin degradation in cultured colon carcinoma.

1989 • 34 citations

Plasminogen activator secretion by established lines of human ovarian carcinoma cells in vitro

1988 • 27 citations

Detection of activated lymphocyte subsets by fluorescence and MTT staining

1989 • 19 citations

Urokinase plasminogen activator in ovarian cancer.

1996 • 17 citations